Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for argenex SE (ARGX : NSDQ)

• Company Description    argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. Number of Employees: 1,599

• Price / Volume Information    Yesterday's Closing Price: $840.95 Daily Weekly Monthly 20 Day Moving Average: 247,908 shares Shares Outstanding: 61.57 (millions) Market Capitalization: $51,776.39 (millions) Beta: 0.38 52 Week High: $934.62 52 Week Low: $510.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.19% -8.03% 12 Week 4.48% 2.79% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL LAARDERHOOGTWEG 25 - AMSTERDAM,P7 1101EB NLD ph: 31-10-703-8441 fax: - aroy@argenx.com http://www.argenx.com

• General Corporate Information    Officers Tim Van Hauwermeiren - Chief Executive Officer and Director Karen Massey - Chief Operating Officer Karl Gubitz - Chief Financial Officer Arjen Lemmen - Vice-President Corporate Development & Strategy Werner Lanthaler - Director Peer Information argenex SE (CORR.) argenex SE (RSPI) argenex SE (CGXP) argenex SE (BGEN) argenex SE (GTBP) argenex SE (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04016X101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 61.57 Most Recent Split Date: (:1) Beta: 0.38 Market Capitalization: $51,776.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $6.47 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $28.91 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 54.68% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: 29.09 Trailing 12 Months: 64.29 PEG Ratio: 0.53 Price Ratios Price/Book: 8.44 Price/Cash Flow: 283.10 Price / Sales: 14.04 EPS Growth vs. Year Ago Period: 272.66% vs. Previous Quarter: 38.50% Sales Growth vs. Year Ago Period: 95.51% vs. Previous Quarter: 19.04% ROE 12/31/25 - - 09/30/25 - 29.78 06/30/25 - 21.06 ROA 12/31/25 - - 09/30/25 - 25.81 06/30/25 - 18.25 Current Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 5.60 Quick Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 5.27 Operating Margin 12/31/25 - - 09/30/25 - 23.41 06/30/25 - 19.53 Net Margin 12/31/25 - - 09/30/25 - 41.58 06/30/25 - 40.98 Pre-Tax Margin 12/31/25 - - 09/30/25 - 26.09 06/30/25 - 21.24 Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - 99.60 Inventory Turnover 12/31/25 - - 09/30/25 - 2.00 06/30/25 - 1.73 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - 0.00

Powered by Zacks Investment Research ©